Home Archives 2013 July

Monthly Archives: July 2013

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for June 29 2013

TradenameApplicantGeneric Name Patent Expiration
DDAVP
Sanofi Aventis Us
desmopressin acetate
Jun 29, 2013
DDAVP (NEEDS NO REFRIGERATION)
Sanofi Aventis Us
desmopressin acetate
Jun 29, 2013

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Infographics

Top
selling drugs

What are the Top-selling Drugs?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for June 28 2013

TradenameApplicantGeneric Name Patent Expiration
EFFEXOR XR
Wyeth Pharms Inc
venlafaxine hydrochloride
Jun 28, 2013

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Infographics

Which drugs have the most patents

Which Drugs Have the Most Patents?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for June 25 2013

TradenameApplicantGeneric Name Patent Expiration
CARDIZEM LA
Valeant Intl
diltiazem hydrochloride
Jun 25, 2013
DILTIAZEM HYDROCHLORIDE
Biovail
diltiazem hydrochloride
Jun 25, 2013
OPTISON
Ge Healthcare
albumin human
Jun 25, 2013
TIAZAC
Valeant Intl
diltiazem hydrochloride
Jun 25, 2013
TYGACIL
Wyeth Pharms Inc
tigecycline
Jun 25, 2013

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Infographics

Which patents protect the most drugs

Which Patents Cover the Most Drugs?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

worldview-5-yearsFive years ago I built a biotechnology innovation index and I have been using it since tracking global biotechnology innovation in Scientific American’s Worldview. It has been a very rewarding project, and I have enjoyed the opportunity to present my research data at international conferences, business schools, and even National Defense University.

Now, Worldview’s editor Mike May has compared my innovation scores with the Venture Capital and Private Equity Country Attractiveness (VCPECA) index. I was quite pleased to see a relatively strong correlation between my innovation index and the VCPECA index.

I am always looking for feedback on the index and opportunities to expand it. I invite you to visit the scorecard at http://www.saworldview.com/wv/scorecard/ and send me your suggestions and feedback.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for June 25 2013

TradenameApplicantGeneric Name Patent Expiration
CARDIZEM LA
Valeant Intl
diltiazem hydrochloride
Jun 25, 2013
DILTIAZEM HYDROCHLORIDE
Biovail
diltiazem hydrochloride
Jun 25, 2013
OPTISON
Ge Healthcare
albumin human
Jun 25, 2013
TIAZAC
Valeant Intl
diltiazem hydrochloride
Jun 25, 2013
TYGACIL
Wyeth Pharms Inc
tigecycline
Jun 25, 2013

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Infographics

Which pharma companies have the most drug patents

Which Companies Have the Most Active Drug Patents?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

Image courtesy of Biswarup Ganguly, via Wikimedia Commons

The 1980 Supreme Court decision in Diamond v. Chakrabarty established the patentability of human modifications to bacteria, and arguably laid the foundation for the biotechnology industry.

Professor Chakrabarty remains an active researcher, and is currently pursing a promising anti-cancer therapy. Given his unique perspective on patenting in biotechnology, I asked him to provide a personal perspective on the recent Myriad ruling. His commentary on patenting human genes and mutations appears as an open access paper in the latest issue of the Journal of Commercial Biotechnology.

I invite you to read Professor Chakrabarty’s commentary and sound off in the comments below.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for June 18 2013

TradenameApplicantGeneric Name Patent Expiration
RILUTEK
Covis Pharma Sarl
riluzole
Jun 18, 2013

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Infographics

Which drug companies face the most patent expirations

Which Companies Face the Most Patent Expirations?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

bioentrepreneurship-bootcampThe Journal of Commercial Biotechnology announces the publication of the July 2013 issue, featuring new papers on biotechnology management and commercialization.

Journal of Commercial Biotechnology Vol 19, Issue 3 (2013)

Patenting human genes and mutations: A personal perspective
Ananda Mohan Chakrabarty
Full details at the Journal of Commercial Biotechnology

The polyvalent scientist: the added value of management training
Maria Theodosiou, Arsia Amir-Aslani
The PhD is becoming more and more prevalent as a degree. However, PhD students are not adequately prepared for careers outside academia and most of them have trouble translating their skills to the job market. The biotech sector is a science-driven industry that is now mature and flourishing and requires business leaders that are technically trained…
Full details at the Journal of Commercial Biotechnology

A Role for Virtual Biotechnology Companies in Drug Discovery and Development?
Dianne Nicol, Johnathon Liddicoat, Christine Critchley
The orthodox business model of many drug discovery and development companies centres on adding value to early-stage discoveries prior to engaging with large pharmaceutical companies to bring products to market. Anecdotal observations suggest some companies are moving to a ‘virtual’ business model – instead of employing in-house scientists, a skeletal management team runs the company and out-sources all research and development…
Full details at the Journal of Commercial Biotechnology

The role of specialization in mutual fund investment strategies: An exploratory study of the life sciences industry.
Osne Frans Kirzner, Lorraine Marie Uhlaner
This paper explores possible differences in investment strategies between specialty and non-specialty funds in the life sciences industry…
Full details at the Journal of Commercial Biotechnology

Culture and the Principles of Biomedical Ethics
Kola Abimbola
This paper examines the roles of culture in the principles of biomedical ethics.  Drawing on examples from African, Navajo and Western cultures, the paper maintains that various elements of culture are indispensable to the application of the principles of biomedical ethics. Full details at the

The relevance and importance of business development and licensing in the biopharmaceutical industry.
Roger Davies
The importance of the business development and licensing (BD&L) function in the global biopharmaceutical industry has grown significantly over the past 20 years as pharmaceutical companies have sought to supplement their internal R&D with innovative products and technologies sourced from biotechnology and drug delivery companies…
Full details at the Journal of Commercial Biotechnology

Patent Licensing Considerations for Biologics under the BPCIA
Sheila Swaroop, Carol Pitzel Cruz
Full details at the Journal of Commercial Biotechnology

Evergreening patents: The Indian Supreme Court rejects patenting of incremental improvements
Joanna Brougher
On April 1, 2013, the Supreme Court in India handed down its decision to dismiss Swiss drug maker Novartis AG’s attempt to win patent protection for its cancer drug Glivec…
Full details at the Journal of Commercial Biotechnology

The life sciences industry and the changing IP landscape
Gareth Williams
This article looks at the findings of Marks & Clerk’s 2013 Life Sciences Report, launched in April 2013. Of interest to both R&D/IP experts and professionals in strategic positions within biotechnology companies, it explores many of the issues facing the biotechnology industry and is informed by an industry survey of over 330 international life sciences professionals…
Full details at the Journal of Commercial Biotechnology

EU Legal & Regulatory Update
Ewan Grist
Full details at the Journal of Commercial Biotechnology

Book Review: The crowdfunding revolution: How to raise venture capital using social media
Steven S. Ma
Full details at the Journal of Commercial Biotechnology